Polymer incorporation into implantable biological tissue to inhibit calcification

• US 4,481,009 A
• Filed: 05/13/1982
• Issued: 11/06/1984
• Est. Priority Date: 05/13/1982
• Status: Expired due to Term

• Current Assignee: Edwards Lifesciences Corporation
• Original Assignee: American Hospital Supply Corp. (Baxter International Inc.)
• Inventors: Nashef, Aws S.
• Primary Examiner(s): Clingman, A. Lionel
• Application Number:
  US06/377,747
• Time in Patent Office: 908 Days
• Field of Search: 8/94.11, 8/94.21, 8/594, 8/586, 3/1.5
• US Class Current: 8/94.11
• CPC Class Codes: A61L 2400/02 Treatment of implants to prevent calcification or mineralisation in vivo
• CPC Class Codes: A61L 27/3687 characterised by the use of chemical agents in the treatment, e.g. specific enzymes, detergents, capping agents, crosslinkers, anticalcification agents
• CPC Class Codes: A61L 27/507 for artificial blood vessels apparatus for applying cells on a blood vessel prosthesis A61F2/062

Abstract

A process for the preparation of implantable biological tissue, and in particular bioprosthetic heart valves, which are prone to calcification after implantation. The process includes the incorporation of biocompatible polymers into the tissue in an amount effective in reducing calcification of the implanted tissue.

Claims

1. A process for treating animal biological tissue prior to implantation in an animal to reduce calcification of said tissue after implantation comprising the steps of:

(a) fixing said tissue under tissue fixing conditions;

(b) contacting said fixed tissue with a first solution of a monomer capable of further polymerization for a time sufficient to covalently bind said monomer directly to the tissue; and

(c) contacting said tissue with a second monomer solution under polymerization conditions such that said second monomer polymerizes with said first monomer bound to said tissue in an amount effective in reducing calcification of said tissue after implantation.

2. The process of claim 1 further comprising the step of removing non-covalently bound monomer from said tissue between steps (b) and (c).

3. The process of claim 1 wherein said first monomer is acrylic acid or methacrylic acid.

4. The process of claim 1 wherein said second monomer solution comprises acrylamide, acrylic acid, acrylic acid ester, methacrylic acid, or methacrylamide.

5. The process of claim 1 wherein said first monomer is acrylic acid or methacrylic acid, and said second monomer solution comprises acrylamide, acrylic acid, acrylic acid ester, methacrylic acid, or methacrylamide.

6. The process of claim 1 wherein the first monomer covalently bound to said tissue is acrylic acid, and the second monomer solution comprises acrylamide and bisacrylamide.

7. The process of claim 2 wherein the first monomer covalently bound to said tissue is acrylic acid, and the second monomer solution comprises acrylamide and bisacrylamide.

8. The process of claim 6 or 7 wherein the second monomer solution contains from about 0.5 to about 6 weight percent acrylamide.

9. The process of claim 8 wherein the second monomer solution further contains about 0.25 weight percent bisacrylamide.

10. The process of claim 1 or 2 wherein said biological tissue is tendon, ligament, heart valve, dura meter, or pericardium.

11. The process of claim 10 wherein said biological tissue is fixed with glutaraldehyde.

12. A process of treating animal biological tissue prior to implantation in an animal to reduce calcification of said tissue after implantation comprising the steps of:

(a) fixing said tissue under tissue fixing conditions;

(b) covalently binding a spacer to said fixed tissue;

(c) contacting said fixed tissue with a first solution of a a monomer capable of further polymerization for a time sufficient to covalently bind said monomer to the spacer; and

(d) contacting said tissue with a second monomer solution under polymerization conditions such that said second monomer polymerizes with said first monomer bound to said tissue through said spacer in an amount effective in reducing calcification of said tissue after implantation.

13. The process of claim 12 further comprising the step of removing non-covalently bound monomer from said tissue between steps (c) and (d).

14. The process of claim 12 wherein said first monomer is acrylic acid or methacrylic acid.

15. The process of claim 12 wherein said spacer is a diamine compound.

16. The process of claim 12 wherein said tissue is contacted with carbodiimide between steps (c) and (d).

17. The process of claim 12 wherein said second monomer solution comprises acrylamide, acrylic acid, acrylic acid ester, methacrylic acid, or methacrylamide.

18. The process of claim 12 wherein said first monomer is acrylic acid or methacrylic acid, and said second monomer solution comprises acrylamide, acrylic acid, acrylic acid ester, methacrylic acid, or methacrylamide.

19. The process of claim 13 wherein the first monomer covalently bound to said tissue is acrylic acid, and the second monomer solution comprises acrylamide and bisacrylamide.

20. The process of claim 17 wherein the second monomer solution contains from about 0.5 to about 6 weight percent acrylamide.

21. The process of claim 15 wherein said diamine compound has the formula

22. The process of claim 20 wherein the second monomer solution further contains about 0.25 weight percent bisacrylamide.

23. The process of claim 12 or 13 wherein said biological tissue is tendon, ligament, heart valve, dura meter, or pericardium.

24. The process of claim 23 wherein said biological tissue is fixed with glutaraldehyde.

31. A bioprosthetic heart valve having a reduced tendency toward calcification after implantation in an animal, said heart valve comprising animal biological tissue having crosslinked hydrophilic polymers covalently immobilized thereon according to the process of claim 2 or 13.

25. A process for treating animal biological tissue prior to implantation in an animal to reduce calcification of said tissue after implantation comprising the steps of:

(a) fixing said tissue under tissue fixing conditions;

(b) contacting said tissue with a first monomer capable of further polymerization for a time sufficient to impregnate said monomer in said tissue; and

(c) contacting said tissue with a second monomer solution under polymerization conditions such that said second monomer polymerizes with said first monomer impregnated within said tissue in an amount effective in reducing calcification of said tissue after implantation.

26. The process of claim 25 wherein said first monomer is acrylic acid or methacrylic acid.

27. The process of claim 25 or 26 wherein said second monomer solution comprises acrylamide, acrylic acid, acrylic acid ester, methacrylic acid, or methacrylamide.

28. A method for reducing calcification of fixed animal biological tissue after implantation in an animal comprising:

covalently immobilizing a monomer capable of further polymerization onto said biological tissue, and polymerizing a second monomer which may be the same as the first monomer with said first monomer immobilized on said tissue prior to implantation in an amount effective in reducing calcification after implantation.

29. The method of claim 28 wherein said first monomer is acrylic or methacrylic acid which is covalently bound to said tissue;

said second monomer is acrylamide, acrylic acid, acrylic acid ester, methacrylic acid, or methacrylamide; and

said tissue is fixed with glutaraldehyde.

30. The method of claim 29 wherein the biological tissue is tendon, ligament, heart valve, dura mater, or pericardium.